DeepMed Research

NCIC Clinical Trials Group

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: letrozole
Other: Placebo

First Posted Date: 2005-10-13

Last Posted Date: 2020-04-02

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 68

Registration Number: NCT00238316

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦
Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada
🇨🇦
Tom Baker Cancer Centre - Calgary, Calgary, Alberta, Canada

and more 7 locations

AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)

Phase 1

Completed

Conditions: Lung Cancer
Colorectal Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: capecitabine
Drug: carboplatin
Drug: cediranib maleate
Drug: paclitaxel

First Posted Date: 2005-04-06

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 50

Registration Number: NCT00107250

Locations: 🇨🇦
Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2004-11-09

Last Posted Date: 2013-05-17

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 17

Registration Number: NCT00095953

Locations: 🇨🇦
Fraser Valley Cancer Centre at British Columbia Cancer Agency, Surrey, British Columbia, Canada
🇨🇦
British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦
Toronto Sunnybrook Regional Cancer Centre at Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada

and more 4 locations

SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer

Phase 2

Completed

Conditions: Liver Cancer

First Posted Date: 2004-11-09

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 15

Registration Number: NCT00095992

Locations: 🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada
🇨🇦
Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

and more 1 locations

Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2004-10-08

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 28

Registration Number: NCT00093457

Locations: 🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦
Tom Baker Cancer Centre - Calgary, Calgary, Alberta, Canada

and more 4 locations

Immediate Compared With Delayed Chemotherapy in Advanced Colorectal Cancer Without Signs or Symptoms of Disease

Phase 3

Completed

Conditions: Colorectal Cancer

Interventions: Drug: fluorouracil
Drug: leucovorin calcium

First Posted Date: 2004-08-31

Last Posted Date: 2020-04-06

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 67

Registration Number: NCT00002570

Locations: 🇺🇸
Quain & Ramstad Clinic, P.C., Bismarck, North Dakota, United States
🇺🇸
Rapid City Regional Hospital, Rapid City, South Dakota, United States
🇺🇸
CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States

and more 13 locations

Pilocarpine in Treating Patients With Dry Mouth Caused by Opioids

Phase 3

Terminated

Conditions: Oral Complications
Quality of Life

Interventions: Drug: Placebo
Drug: pilocarpine hydrochloride

First Posted Date: 2004-08-17

Last Posted Date: 2020-04-03

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 4

Registration Number: NCT00003686

Locations: 🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada
🇨🇦
Humber River Regional Hospital, Weston, Ontario, Canada

Theophylline in Treating Cancer Patients With Shortness of Breath

Phase 3

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Pulmonary Complications
Quality of Life

First Posted Date: 2004-08-17

Last Posted Date: 2020-04-03

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 3

Registration Number: NCT00003684

Locations: 🇨🇦
Kingston Regional Cancer Centre, Kingston, Ontario, Canada
🇨🇦
Algoma District Medical Group, Sault Sainte Marie, Ontario, Canada
🇨🇦
Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada

and more 1 locations

ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: ISIS 5132

First Posted Date: 2004-08-05

Last Posted Date: 2020-04-06

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 22

Registration Number: NCT00003892

Locations: 🇨🇦
Northwestern Ontario Regional Cancer Centre, Thunder Bay, Thunder Bay, Ontario, Canada
🇨🇦
Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada
🇨🇦
Centre Hospitalier Universitaire de Quebec, Pavillion de Quebec, Quebec City, Quebec, Canada

and more 63 locations

Tamoxifen in Treating Women With High-Risk Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2004-07-29

Last Posted Date: 2020-04-01

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 672

Registration Number: NCT00002542

Locations: 🇨🇦
Credit Valley Hospital, Mississauga, Canada
🇨🇦
Cancer Centre of Southeastern Ontario at Kingston, Kingston, Canada
🇨🇦
Stronach Regional Health Centre at Southlake, Newmarket, Canada

and more 45 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy